Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)

• Published in: Transplantation and cellular therapy Vol. 30; no. 6; pp. 601.e1 - 601.e13
• Main Authors: Benítez Carabante, María Isabel, Bueno, David, Alonso García, Laura, López Torija, Iván, Marsal, Julia, Fernandez Navarro, José María, Uria Oficialdegui, María Luz, Panesso, Melissa, Molina, Blanca, Beléndez Bieler, Cristina, Palomo, Pilar, Pérez Martínez, Antonio, Diaz-de-Heredia, Cristina
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2024
• Subjects: Adolescent; Antibodies, Monoclonal, Humanized - therapeutic use; Child; Child, Preschool; Children; Complement Inactivating Agents - therapeutic use; Eculizumab; Female; Hematopoietic stem cell transplantation (HSCT); Hematopoietic Stem Cell Transplantation - adverse effects; Humans; Infant; Male; Retrospective Studies; Risk Factors; Spain - epidemiology; Thrombotic Microangiopathies - drug therapy; Thrombotic Microangiopathies - etiology; Transplantation-associated thrombotic microangiopathy (TA-TMA); Treatment Outcome; Spain; Eculizumab; Children; Transplantation-associated thrombotic microangiopathy (TA-TMA); Hematopoietic stem cell transplantation (HSCT)
• ISSN: 2666-6367; 2666-6367
• DOI: 10.1016/j.jtct.2024.03.019

•Experience with eculizumab to treat post-transplantation microangiopathy is increasing.•More than 60% of patients respond to eculizumab.•Survival is superior in patients who respond to eculizumab compared to nonresponders.•Lung involvement is the main risk factor for response. Transplantation-associated thrombotic microangiopathy (TA-TMA) is associated with high morbidity and mortality. Although survival has improved significantly with the introduction of eculizumab, the need for improvement remains, especially in high-risk patients. This study aimed to describe the results obtained with eculizumab in a pediatric cohort with the attempt to define which risk factors could determine the response to treatment. We designed a national multicenter retrospective study of children treated with eculizumab for high-risk TA-TMA. The study cohort comprised 29 patients who had undergone a first (n = 28) or second (n = 1) allogeneic hematopoietic stem cell transplantation (HSCT) for malignant (n = 17) or nonmalignant (n = 12) disease. The median time from HSCT to TA-TMA diagnosis was 154 days (interquartile range [IQR], 103 to 263 days). Eleven patients (38%) who were initially diagnosed with low- to intermediate-risk TA-TMA progressed to high-risk TA-TMA (hrTA-TMA), within a median time of 4 days (IQR, 1 to 33 days). SC5b-9 was increased in 90% of 20 patients in whom it was measured. Renal (n = 12), pulmonary (n = 1), and intestinal (n = 1) biopsy confirmed the diagnosis in 12 of 14 patients (85%). Seventeen patients (58%) had extrarenal involvement with serositis (n = 13; 44,8%), pulmonary (n = 12; 41,4%), gastrointestinal (n = 8; 27.6%), cardiovascular (n = 7; 24.1%), or central nervous system (CNS) (n = 2; 6.9%) involvement. The median time from hrTA-TMA diagnosis to the initiation of eculizumab was 7 days (IQR, 1 to 8 days). Overall, 19 patients (65.5%) responded to eculizumab, of whom 17 (58.6%) achieved a complete response and 2 (6.9%) achieved a partial response. The remaining 10 patients (34.5%) did not show any of response. The overall response rate to eculizumab for TA-TMA was 27.59% (95% confidence interval [CI], 14.87% to 47.66%) at 1 month, 55.17% (95% CI, 38.43% to 73.48%) at 3 months, and 62.07% (95% CI, 45.10% to 79.13%) at 6 months after eculizumab initiation. In multivariate analysis, the pulmonary involvement decreased the probability of response (hazard ratio [HR], .18; P = .0298). The 1-year overall survival (OS) was 55.2% (95% CI, 35.6% to 71.0%) for the whole cohort and 83.3% (95% CI, 56.7% to 94.3%) for patients who responded to eculizumab. Pulmonary involvement (HR, 14.93; P = .0043) and CNS involvement (HR, 8.63; P = .0497) were associated with a statistically significant decrease in survival. We found that patients diagnosed with hrTA-TMA with pulmonary involvement had a poor response to eculizumab, and that patients with pulmonary and CNS involvement had significantly decreased survival. Given these results, we hypothesize that providing eculizumab therapy at an early stage of the disease before organ damage is established might significantly improve the response and, consequently, survival.